Oncology & Cancer

Drug mechanism opens door for new anti-cancer immunotherapies

Researchers have revealed a new mechanism of targeted drug treatment used against chronic lymphocytic leukemia, through the promotion of immune cell function, that could be exploited using new anti-cancer immunotherapies.

Oncology & Cancer

A possible new treatment for acute myeloid leukemia

New research has identified a novel immunotherapy for acute myeloid leukemia. The study, published in Nature Cancer, describes a T-cell receptor that recognizes a mutation shared between a subgroup of patients with the disease. ...

Immunology

Making immunotherapy safe for AML

Acute myeloid leukemia (AML), the second most common leukemia in children, is hard to treat and has a five-year survival rate of just 65 to 70%, according to the American Cancer Society. While immunotherapies like monoclonal ...

Oncology & Cancer

AGO2 in T-prolymphocytic leukemia (T-PLL)

A new editorial paper titled "AGO2 in T-prolymphocytic leukemia: its canonical and noncanonical deregulation and function" has been published in Oncotarget.

page 4 from 40